MUCPHARM
Clinical stage bio-pharma company focused on the treatment of mucin-containing and secreting cancers. Bromelain and acetylcysteine, BromAcâ„¢, is a patented combination drug developed by our team for mucinous cancers, where the drug affects glycosidic linkages and disulphide bonds in glycoproteins including mucinous tumours. Bromelain is an enzyme extracted from pineapple stem or fruit (ananas comosus) and it is made up of a number of enzymes (proteases, carbohydrases, phosphatases, peroxidases,... etc.) that gives it unique enzymatic properties for the hydrolysis of glycosidic bonds in complex carbohydrates. As a therapeutic molecule, it is currently used as a mucolytic in combination with acetylcysteine with anticancer properties for the treatment of mucinous tumours. It combines synergistically with a variety of anticancer drugs.
MUCPHARM
Industry:
Biopharma Biotechnology Life Science Pharmaceutical Therapeutics
Founded:
2016-01-01
Address:
Kogarah, New South Wales, Australia
Country:
Australia
Website Url:
http://www.mucpharm.com
Total Employee:
11+
Status:
Active
Contact:
+61 2 9113 2070
Total Funding:
6 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics
Similar Organizations
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Investors List
Herzberg Family Office
Herzberg Family Office investment in Seed Round - Mucpharm
Official Site Inspections
http://www.mucpharm.com Semrush global rank: 8.15 M Semrush visits lastest month: 359
- Host name: 198.49.23.145
- IP address: 198.49.23.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Mucpharm"
Mucpharm BromAc
Our company was established by a group of clinicians and scientists, who specialise in treating patients with advanced cancers of the peritoneum. Mucpharm’s aim is to develop BromAc® for …See details»
About Us - Mucpharm BromAc
Our company was established by a group of clinicians and scientists, who specialise in treating patients with advanced cancers of the peritoneum. Mucpharm’s aim is to develop BromAc® for a rare disease in oncology, known …See details»
About Us — Mucpharm BromAc
Mucpharm is a specialised oncology company focused on the treatment of mucin-containing and secreting cancers. Mucpharm was established by our group of clinicians and scientists, who …See details»
Mucpharm - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +61 2 9113 2070 Clinical stage bio-pharma company focused on the treatment of mucin-containing and secreting cancers.See details»
Mucpharm - VentureRadar
Website: https://mucpharm.com/ Develops specialized oncology treatments targeting mucin-containing and secreting cancers, aiming to improve patient outcomes by sensitizing cells to …See details»
Mucpharm - Overview, News & Similar companies | ZoomInfo.com
Mucpharm contact info: Phone number: +61 291132070 Website: www.mucpharm.com What does Mucpharm do? Mucpharm is a specialised oncology company focused on the treatment …See details»
Mucpharm - Funding, Financials, Valuation & Investors - Crunchbase
Mucpharm is a clinical-stage biopharma company focused on the treatment of mucin-containing and secreting cancers.See details»
Mucpharm - Crunchbase
Mucpharm is a clinical-stage biopharma company focused on the treatment of mucin-containing and secreting cancers.See details»
Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural ...
Bromelain and acetylcysteine (BromAc®) is a novel treatment modality that has demonstrated mucolytic properties. When injected directly into mucinous disease, it facilitates …See details»
Mucpharm - Contacts, Employees, Board Members, Advisors
Mucpharm is a clinical-stage biopharma company focused on the treatment of mucin-containing and secreting cancers.See details»
Acetylcysteine/bromelain (Mucpharm) - Drug Targets, Indications ...
Increasingly sticky sputum is associated with critical illness, with considerably raised levels of a specific type of mucous protein (MUC5AC) in sputum in COVID-19 patients.See details»
Publications — Mucpharm BromAc
Publications from Mucpharm and Collaborative Research Groups. Valle N, Eapen MS, Pillai K, Morris R, Akhter J, Mekkawy AH, Morris DL, Valle SJ. Impact of Nebulized BromAc® on …See details»
Ex-vivo mucolytic and anti-inflammatory activity of BromAc in …
Apr 1, 2022 · BromAc is a strong mucolytic for COVID-19 sputum ex vivo. Select chemokines and cytokines were downregulated following BromAc exposure. Mucolytic and anti-inflammatory …See details»
Long-Term Treatment of Unresectable Pseudomyxoma Peritonei …
Dec 8, 2023 · Percutaneous drainage of mucin may be a non-surgical option for relief of symptoms; however, it remains difficult due to the high viscosity of mucin, with numerous case …See details»
In vitro study of BromAc on SARS-CoV-2 spike and envelope
Sep 8, 2020 · Objectives SARS-CoV-2 infection is the cause of a worldwide pandemic, currently with limited therapeutic options. It is characterised by being highly contagious and nasal …See details»
Oncology — Mucpharm BromAc
Mucpharm’s BromAc® is a patented drug combination that has a dramatic synergistic effect on the dissolution of tumour-produced mucin. In addition, BromAcâ„¢ has a major …See details»
Opportunities — Mucpharm BromAc
Mucpharm is exploring partnering and/or licensing opportunities in the rare disease, respiratory and oncology fields. For more information, please contact us: [email protected]. …See details»
The combination of Bromelain and Acetylcysteine (BromAc ...
Dec 21, 2020 · BromAc (Bromelain & Acetylcysteine) has synergistic action against glycoproteins by the synchronous breakage of glycosidic linkages and disulfide bonds.See details»
Effect of nebulised BromAc - bioRxiv
Dec 28, 2021 · Since earlier studies have shown success with BromAc ® as mucolytic agent for treating a rare disease known as pseudomyxoma peritonei (PMP), we tested the formulation …See details»
Respiratory — Mucpharm BromAc
Our respiratory tract secretes mucus into our lungs as an immune defence barrier, clearing out inspired particulates and pathogens by coughing or forced expiration, protecting us from …See details»